{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:18:19Z","timestamp":1771510699986,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to better understand the relapse rate for eosinophilic granulomatosis with polyangiitis, a rare, debilitating form of vasculitis, in Japanese elderly and non-elderly patients, along with their treatment statuses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational study used claims data from April 2019 to March 2022 representing approximately 8 million insured individuals in Japan. Patients aged\u2009\u226518\u2009years were identified and stratified into elderly (\u226565\u2009years) and non-elderly (&amp;lt;65\u2009years) groups. The proportion of patients experiencing relapses and their treatment statuses were assessed during a 1-year follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 651 eligible patients with eosinophilic granulomatosis with polyangiitis enrolled, 38.86% experienced a relapse during the follow-up period. This proportion was similar between the elderly (36.34%) and non-elderly (42.59%) groups. Moreover, fewer elderly than non-elderly patients were prescribed biologics (22.16% vs. 37.26%) and immunosuppressants (20.36% vs. 29.28%), despite having higher percentages of corticosteroid-related comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The disease burden of eosinophilic granulomatosis with polyangiitis in Japan remains substantial, with over one-third of patients experiencing a relapse, regardless of age. Age-specific management strategies optimizing biologics and immunosuppressant use while minimizing adverse events are needed to improve the outcomes of these patients in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf026","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T08:41:23Z","timestamp":1742287283000},"page":"884-893","source":"Crossref","is-referenced-by-count":1,"title":["Relapses and treatment status in elderly and non-elderly patients with eosinophilic granulomatosis with polyangiitis: A retrospective observational study using Japanese nationwide claims data"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2959-9036","authenticated-orcid":false,"given":"Masami","family":"Taniguchi","sequence":"first","affiliation":[{"name":"Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital , Sagamihara, Kanagawa,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Saga University , Saga,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Oka","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Ono","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sumi","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Arita","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Makita","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University , Kawagoe, Saitama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2026021908163973500_R1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026021908163973500_R2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026021908163973500_R3","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/mr\/road104","article-title":"Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis","volume":"35","author":"Sada","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026021908163973500_R4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/mr\/roab007","article-title":"The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study","volume":"32","author":"Sada","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026021908163973500_R5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026021908163973500_R6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/keh522","article-title":"ANCA-associated renal vasculitis at the end of the twentieth century\u2014a disease of older patients","volume":"44","author":"Harper","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2026021908163973500_R7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MD.0b013e31817c744b","article-title":"Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients","volume":"87","author":"Chen","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"2026021908163973500_R8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s11255-014-0717-y","article-title":"Clinical outcomes of ANCA-associated vasculitis in elderly patients","volume":"46","author":"Haris","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"2026021908163973500_R9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/joim.13417","article-title":"Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: a multicentre cohort study","volume":"291","author":"Thietart","year":"2022","journal-title":"J Intern Med"},{"key":"2026021908163973500_R10","first-page":"190","article-title":"Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people","volume":"5","author":"Okada","year":"2022","journal-title":"JMA J"},{"key":"2026021908163973500_R11","doi-asserted-by":"crossref","DOI":"10.1265\/ehpm.22-00106","article-title":"Development and validation of ischemic heart disease and stroke prognostic models using large-scale real-world data from Japan","volume":"28","author":"Yoshida","year":"2023","journal-title":"Environ Health Prev Med"},{"key":"2026021908163973500_R12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2215\/CJN.05350515","article-title":"Treating elderly patients with ANCA-associated vasculitis","volume":"10","author":"Jefferson","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021908163973500_R13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2026021908163973500_R14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Series B Methodol"},{"key":"2026021908163973500_R15","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1007\/s10067-021-05783-8","article-title":"Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis","volume":"40","author":"Jakes","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026021908163973500_R16","first-page":"1249","article-title":"Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States","volume":"27","author":"Bell","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2026021908163973500_R17","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3899\/jrheum.171352","article-title":"Longterm outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis","volume":"45","author":"Saku","year":"2018","journal-title":"J Rheumatol"},{"key":"2026021908163973500_R18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021908163973500_R19","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021908163973500_R20","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02341-6","article-title":"Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies","volume":"22","author":"Sada","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026021908163973500_R21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019173","article-title":"Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study","volume":"99","author":"Waki","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026021908163973500_R22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00198-022-06657-8","article-title":"Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review","volume":"34","author":"Chandran","year":"2023","journal-title":"Osteoporos Int"},{"key":"2026021908163973500_R23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.resinv.2021.02.010","article-title":"Real-world treatment and health care resource use among severe asthma patients in Japan","volume":"59","author":"To","year":"2021","journal-title":"Respir Investig"},{"key":"2026021908163973500_R24","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3899\/jrheum.161436","article-title":"Longterm prognosis of 121 patients with eosinophilic granulomatosis with polyangiitis in Japan","volume":"44","author":"Tsurikisawa","year":"2017","journal-title":"J Rheumatol"},{"key":"2026021908163973500_R25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/annrheumdis-2016-209233","article-title":"Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative","volume":"75","author":"Baillet","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026021908163973500_R26","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.","volume":"33","author":"Han","year":"2006","journal-title":"J Rheumatol"},{"key":"2026021908163973500_R27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299192","article-title":"Causal associations between rheumatoid arthritis, cataract and glaucoma in European and East Asian populations: A bidirectional two-sample mendelian randomization study.","volume":"19","author":"Teng","year":"2024","journal-title":"PLoS One"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf026\/62443869\/roaf026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/5\/884\/62443869\/roaf026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/5\/884\/62443869\/roaf026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:16:46Z","timestamp":1771507006000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/5\/884\/8084820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf026","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,18]]}}}